literature

HIV mutation literature information.

Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.

PMID: 21487249 2011 AIDS (London, England)

Result: Five infants had NVP resistance mutations other than K103N and Y181C detected by ViroSeq at 14 weeks (V106A, Y188C/L, G190A) in the absence of K103N or Y181C.

Discussion: Five infants had other NVP resistance mutations detected at 14 weeks of age in the absence of K103N or Y181C (V106A, Y188C/L and G190A).

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo.

PMID: 21663632 2011 Journal of the International AIDS Society

Result: V106A/M, K101E and Y188C/L were noted in four, three and two patients, respectively.

Table: V106A

1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.

PMID: 21903401 2011 Bioorganic & medicinal chemistry

Method: Plasmids encoding RT in which one or two amino acid residues were substituted (L100I, K103N, V106A, Y181C, Y188L, G190A and K103N/Y181C) were constructed by amplifying the gene in two fragments using the oligonucleotides listed in Table S1.

Result: Both benzophenones 17 and 20 retained activity against most HIV-RT forms with the exception of V106A (Table 3).

Result: Both compounds proved to be inactive against the V106A RT, while efavirenz retained activity.

Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).

PMID: 21930388 2011 Bioorganic & medicinal chemistry

Abstract: The most promising compounds in these series are three diarylpyridazinones 25a, 25l and 25n which demonstrated submicromolar activity against wild-type HIV-1 and moderate activity against the single mutant strain Ba-L V106A.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

PMID: 22132100 2011 PloS one

Method: RT mutations were identified from the International AIDS Society USA Drug (IAS-USA) mutation tables, spring 2008 (http://www.iasusa.org/resistance_mutations): M41L, K65R, D67N, insertion 69, K70R/E, L74I/V, L100I, K103N, V106A/M, V108I, Q151M, Y181I/C, M184V, Y188C/L, G190A/S, L210W, T215Y/F,

PMID: 19933797 2010 Antimicrobial agents and chemotherapy

Abstract: NNRTI RAMs emerging in HIV-1 under selective pressure from TMC278 included combinations of V90I, L100I, K101E, V106A/I, V108I, E138G/K/Q/R, V179F/I, Y181C/I, V189I, G190E, H221Y, F227C, and M230I/L.

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

PMID: 20102272 2010 The Journal of infectious diseases

Method: For single-genome sequencing analyses, a total of 27 subjects (15 NNRTI-naive and 12 NNRTI-experienced) were randomly selected from enrollees meeting the following criteria: i) entry sample negative for NNRTI-resistance mutations by standard genotype analysis (ViroSeq platform; Celera, Alameda, CA); ii) reached a protocol-defined virologic failure endpoint by study week 24, and iii) the virologic failure sample had one or more major NNRTI-resistance mutations (L100I, K101E, K103N, V106A or M, V108I, Y181C or I, Y188C, H, or L, G

Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

PMID: 20158398 2010 Clinical infectious diseases

Table: V106A

In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.

PMID: 20219553 2010 Antiviral research

Abstract: Two pathways to loss of susceptibility to RO-0335 were observed, containing patterns of amino acid changes at either V106I/A plus F227C (with additional contributions from A98G, V108I, E138K, M230L and P236L) or V106I/Y188L (with a potential contribution from L100I, E138K and Y181C).

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

PMID: 20453629 2010 AIDS (London, England)

Abstract: M184V/I, K103N and V106A/M were the most common mutations.

Discussion: Thus, M184V/I, K103N and V106A/M were the most common mutations due to lamivudine and NNRTI use.

Browser Board

Co-occurred Entities

Filtrator